- Home
- EWTX vs AGL Comparison
EWTX vs AGL Comparison
Compare EWTX & AGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- AGL
- Stock Information
- Founded
- EWTX 2017
- AGL 2016
- Country
- EWTX United States
- AGL United States
- Employees
- EWTX N/A
- AGL N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- AGL Managed Health Care
- Sector
- EWTX Health Care
- AGL Health Care
- Exchange
- EWTX Nasdaq
- AGL Nasdaq
- Market Cap
- EWTX 1.2B
- AGL 968.6M
- IPO Year
- EWTX 2021
- AGL 2021
- Fundamental
- Price
- EWTX $14.58
- AGL $2.22
- Analyst Decision
- EWTX Buy
- AGL Hold
- Analyst Count
- EWTX 8
- AGL 20
- Target Price
- EWTX $40.13
- AGL $4.47
- AVG Volume (30 Days)
- EWTX 1.1M
- AGL 5.3M
- Earning Date
- EWTX 05-08-2025
- AGL 05-06-2025
- Dividend Yield
- EWTX N/A
- AGL N/A
- EPS Growth
- EWTX N/A
- AGL N/A
- EPS
- EWTX N/A
- AGL N/A
- Revenue
- EWTX N/A
- AGL $5,988,958,000.00
- Revenue This Year
- EWTX N/A
- AGL N/A
- Revenue Next Year
- EWTX N/A
- AGL $9.89
- P/E Ratio
- EWTX N/A
- AGL N/A
- Revenue Growth
- EWTX N/A
- AGL 23.07
- 52 Week Low
- EWTX $10.60
- AGL $1.50
- 52 Week High
- EWTX $38.12
- AGL $7.73
- Technical
- Relative Strength Index (RSI)
- EWTX 43.22
- AGL 31.99
- Support Level
- EWTX $13.80
- AGL $2.15
- Resistance Level
- EWTX $14.68
- AGL $2.57
- Average True Range (ATR)
- EWTX 0.78
- AGL 0.20
- MACD
- EWTX 0.08
- AGL -0.02
- Stochastic Oscillator
- EWTX 29.68
- AGL 7.52
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About AGL agilon health inc.
Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.